By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
𝐁𝐞𝐬𝐭𝐫𝐚𝐭𝐞𝐝𝐑𝐞𝐚π₯𝐭𝐑𝐁𝐞𝐬𝐭𝐫𝐚𝐭𝐞𝐝𝐑𝐞𝐚π₯𝐭𝐑𝐁𝐞𝐬𝐭𝐫𝐚𝐭𝐞𝐝𝐑𝐞𝐚π₯𝐭𝐑
  • Health News
  • Diet & Nutrition
  • Healthy Foods
  • Healthy Drinks
  • Find Doctors
Font ResizerAa
𝐁𝐞𝐬𝐭𝐫𝐚𝐭𝐞𝐝𝐑𝐞𝐚π₯𝐭𝐑𝐁𝐞𝐬𝐭𝐫𝐚𝐭𝐞𝐝𝐑𝐞𝐚π₯𝐭𝐑
Font ResizerAa
  • Health News
  • Diet & Nutrition
  • Healthy Foods
  • Healthy Drinks
  • Find Doctors
Search
  • Health News
  • Diet & Nutrition
  • Healthy Foods
  • Healthy Drinks
  • Find Doctors

Top Stories

Explore the latest updated news!
Scientists Develop Injectable Glucose Sensor Using Ingredient That Costs 90% Less

Scientists Develop Injectable Glucose Sensor Using Ingredient That Costs 90% Less

Why Water Is the Best Drink to Have After Dinner for Healthy Blood Sugar

Scientists Develop Electronic Implant That Controls Blood Sugar in Diabetic Mice

Scientists Develop Electronic Implant That Controls Blood Sugar in Diabetic Mice

Stay Connected

Find us on socials
248.1k Followers Like
61.1k Followers Follow
165k Subscribers Subscribe
Made by ThemeRuby using the Foxiz theme. Powered by WordPress
Google Preferred Source

See more from us on Google

Add this site as a Preferred Source.

𝐁𝐞𝐬𝐭𝐫𝐚𝐭𝐞𝐝𝐑𝐞𝐚π₯𝐭𝐑 > Blog > Health News > No More Injections? New Diabetes Drug Pill Achieves Ozempic-Level Results
Health News

No More Injections? New Diabetes Drug Pill Achieves Ozempic-Level Results

Manoj Prasad
Last updated: November 21, 2025 6:44 pm
By Manoj Prasad
No Comments
Share
SHARE
Moringa Magic Banner

A new pill aimed at treating type 2 diabetes has shown striking results in a large international trial and could significantly shift how obesity and diabetes are managed.

Contents
Trial results and significanceWhy an oral GLP-1 mattersRegulatory outlook, competition, and real-world contextCautions and what still needs to be answeredConclusion

The experimental drug, orforglipron, developed by Eli Lilly and Company, is the first non-peptide, oral small-molecule that acts on the GLP-1 receptor, offering a potential alternative to injectable GLP-1 therapies.

Trial results and significance

In the pivotal Phase 3 trial named ATTAIN-2, 1,613 adults with type 2 diabetes, classified as overweight or obese (with an average age of 57 years and an average weight of ~101 kg), were randomized across 136 sites in 10 countries.

Over 72 weeks, participants took either a placebo or one of three daily doses of orforglipron (6 mg, 12 mg, or 36 mg), along with a diet that included a daily 500-calorie reduction.

The results were compelling:

  • The 36 mg group lost an average of ~9.6% of body weight (β‰ˆ9.6 kg) over the 72 weeks.
  • The 12 mg group lost ~7.0%, and the 6 mg group ~5.1%.
  • The placebo arm lost ~2.5%.
  • Notably, 26% of participants in the highest-dose arm achieved more than 15% weight loss.

These outcomes approach the weight loss typically observed with injectables such as semaglutide (brand name Ozempic when used for diabetes), which often delivers 10 – 15% weight reduction in similar timeframes.

In addition, all dosage arms of orforglipron showed improvements in glycaemic control (lower HbA1c), and secondary markers, including blood pressure, inflammation and cardiovascular risk indicators improved as well.

Side-effect patterns mirrored other GLP-1 therapies: nausea, diarrhoea, vomiting, and constipation were the most common adverse events.

Why an oral GLP-1 matters

Until now, GLP-1 receptor agonist therapies have almost exclusively required injections, largely because the peptide molecules are degraded in the digestive tract and cannot survive oral administration.

The novelty of orforglipron lies in its structure: non-peptide, small-molecule, orally absorbed – yet still engages the GLP-1 receptor and triggers the body’s appetite- and glucose-regulating pathways.

From a patient perspective, the implications are substantial: no needles, potentially lower production and distribution costs, and broader access – especially in populations with needle-aversion or in lower-resource settings.

Experts in the trial noted that for people with type 2 diabetes, achieving double-digit weight loss is especially challenging, and an oral option could open new doors.

Regulatory outlook, competition, and real-world context

Despite the positive results, orforglipron is not yet approved by the U.S. Food and Drug Administration (FDA). According to Eli Lilly, the company plans regulatory filings for obesity treatment in 2025 and for type 2 diabetes in 2026.

In the wider landscape, injectable GLP-1s (semaglutide, tirzepatide, etc) are already showing strong weight-loss and cardiovascular-outcome data; tirzepatide, for example, has achieved ~14.7% weight loss in diabetics in earlier trials.

The fact that orforglipron approaches these numbers with an oral route is what gives it novelty.

In India and other markets, the potential for an affordable oral GLP-1 is causing interest. Lilly has stated intentions to bring orforglipron to India, emphasising the need for non-injectable treatments in contexts where injections carry stigma or logistic hurdles.

Cautions and what still needs to be answered

While the results are exciting, several caveats remain:

  • Long-term cardiovascular outcome data (i.e., effects on heart attack, stroke, death) are not yet available for orforglipron. Many GLP-1 therapies are approved or guided based on cardiovascular-benefit trials.
  • The real-world effectiveness – beyond trial conditions (dietary energy-restriction, high adherence, monitoring) – remains to be seen.
  • Safety over longer horizons needs monitoring. Although side effects matched the GLP-1 class, the oral format invites scrutiny of absorption, metabolism, and liver/kidney interactions.
  • Regulatory and cost-access issues: even if approved, will the drug be affordable and accessible broadly, especially in middle- and low-income countries?

Conclusion

The development of orforglipron marks what may be a turning point in the treatment of obesity and diabetes: a daily pill that mimics the effects of injectable GLP-1 receptor agonists, delivering near double-digit weight loss and improved glycaemic control in type 2 diabetes.

Given the trial outcomes and its non-injectable format, it has the potential to become a widely accessible therapy – perhaps akin to how metformin became foundational in diabetes care.

As the global obesity and type-2-diabetes epidemics continue to rise – particularly in countries like India, where injectable therapies may face additional cultural or logistical barriers – an oral option could shift treatment paradigms.

But with approval still pending and key long-term data pending, the healthcare community will watch closely.

For patients and clinicians alike, the message is cautiously optimistic: soon we may have a needle-free, powerful tool in the fight against diabetes and obesity – transforming what has been an injectable-dominated field.

Study Published: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8/abstract

You Might Also Like

New Study Finds Eating One Avocado Every Day May Lower Bad Cholesterol and Reduce Heart Disease Risk
Study Finds 15 Million Adults Using Hepatotoxic Botanicals Amid Mislabeled Supplements
$200 Weight-Loss Drug Could Drop to Just $3 – Here’s Why
This One Sleep Habit Could Add 4 Years to Your Life
Struggling to Wake Up? 10 Easy Tricks to Make Mornings Less Miserable
Share This Article
Facebook Twitter Copy Link Print
ByManoj Prasad
Follow:
Manoj Prasad is a passionate nutritionist and dietician, known for creating personalized meal plans focused on natural, whole foods. He is also a health writer, sharing insights on healthy eating, nutritious foods and drinks, and the latest in wellness trends to help people make informed choices for better health.
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Your post must include a link to this post.

How does this work?
Write a response on your own website and include a link to this post. Then submit your response’s URL here. Your response may appear here after moderation. To update or remove it, edit or delete your original post and submit the same URL again. Learn more about Webmentions.
- Advertisement -

Related Stories

Uncover the stories that related to the post!
Can Eating Slowly Be the Secret to Weight Loss Science Speaks
Health News

Can Eating Slowly Be the Secret to Weight Loss? Science Speaks

Manoj Prasad
Manoj Prasad
February 9, 2025
Can Vitamin D Lower Blood Sugar Study Says Yes
Health News

Can Vitamin D Lower Blood Sugar? Study Says Yes – Here’s How

Manoj Prasad
Manoj Prasad
July 23, 2025
New Experimental Diabetes Pill Burns Fat Without Ozempic
Health News

New Experimental Diabetes Pill Burns Fat Without Ozempic’s Common Drawbacks

Manoj Prasad
Manoj Prasad
June 6, 2026
Menopausal Symptoms May Increase Risk of Dementia, Study Finds
Health News

Menopausal Symptoms May Increase Risk of Dementia, Study Finds

Manoj Prasad
Manoj Prasad
March 7, 2025
This Simple Diet Could Help Protect You from Cancer
Health News

This Simple Diet Could Help Protect You from Cancer

Manoj Prasad
Manoj Prasad
March 7, 2025
The Surprising Way to Lower Your Diabetes Risk
Health News

Just 4 Minutes a Day: The Surprising Way to Lower Your Diabetes Risk

Manoj Prasad
Manoj Prasad
May 4, 2026
Global Health Alert Sugar-Sweetened Beverages Linked to Millions of Diabetes and Heart Disease Cases
Health News

Global Health Alert: Sugar-Sweetened Beverages Linked to Millions of Diabetes and Heart Disease Cases

Manoj Prasad
Manoj Prasad
January 9, 2025
A glass jar filled with golden, raw honey, with honeycomb pieces beside it. One side of the image shows honey being poured from a honey dipper (representing centrifuged honey), while the other side features honey oozing from a crushed honeycomb (representing pressed honey)
Health News

New Study Reveals Key Differences in Honey Extraction Methods and Their Impact on Quality

Manoj Prasad
Manoj Prasad
March 15, 2025
Show More
Follow US
Copyright Β© 2026 Bestratedhealth.com
  • About Us
  • Team
  • Contact Us
  • Privacy Policy
Welcome Back!

Sign in to your account